Autoimmune disease

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Retrieved on: 
화요일, 3월 5, 2024
MBC, Autoimmune disease, Safety, ASX, Observation, Paclitaxel, Patient, Disease, IMM, Cancer, Pharmaceutical industry

Updated safety data from patients with HR-positive/HER2-negative/low metastatic breast cancer (MBC) treated with this innovative immuno-oncology (IO)-chemotherapy combination reveal no treatment-emergent serious adverse events.

Key Points: 
  • Updated safety data from patients with HR-positive/HER2-negative/low metastatic breast cancer (MBC) treated with this innovative immuno-oncology (IO)-chemotherapy combination reveal no treatment-emergent serious adverse events.
  • Additionally, all treatment-emergent adverse events during the safety observation period to date have been of mild severity.
  • The biologically active 30mg efti dose, previously the highest dose of efti ever tested, has demonstrated a stronger immune response and greater efficacy than lower dosing levels (1mg, 6mg) in multiple clinical trials.
  • The ongoing randomized Phase II portion of the trial, which will include up to 58 evaluable patients, is focused on whether 90mg efti dosing is safe and more efficacious than 30mg dosing.

Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

Retrieved on: 
화요일, 3월 5, 2024
Spleen, Liver, Bangladesh Technical Education Board, Autoimmune disease, NIH, Physician, Extrapyramidal system, Weight loss, Dizziness, AL amyloidosis, Amyloidosis, Diagnosis, Joint, Hypoesthesia, Fatigue, Patient, Heart, Tissue, Mortality

LOS ANGELES, CA, March 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced its new AL Amyloidosis awareness campaign Be Proactive in AL™.

Key Points: 
  • LOS ANGELES, CA, March 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced its new AL Amyloidosis awareness campaign Be Proactive in AL™.
  • The campaign seeks to increase awareness about the critical need to recognize and diagnose AL Amyloidosis early, while also educating AL Amyloidosis patients about available treatment options.
  • AL amyloidosis is a life-threatening immunological disorder in which an abnormal protein called amyloid builds up in tissues and organs.
  • “Today, it is common for AL Amyloidosis patients to see 3 or 4 different physicians and wait months to years before being definitively diagnosed with AL amyloidosis,” said Dena Heath, Amyloidosis Research Consortium Board Secretary and Facilitator, Northern California Amyloidosis Support Group.

Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

Retrieved on: 
화요일, 3월 5, 2024
SAN, Cancer, Kite Pharma, Therapy, Autoimmune disease, PIN, News

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report fourth quarter and full year 2023 financial results and provide a business update on March 14, 2024, after the close of the market.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report fourth quarter and full year 2023 financial results and provide a business update on March 14, 2024, after the close of the market.
  • The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m.
  • The listen-only webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section.
  • If you would like the option to ask a question on the conference call, please use this link to register.

Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors

Retrieved on: 
월요일, 3월 4, 2024
Therapy, Clay, Autoimmune disease, CD47, Drug development, Oregon State University, Pleasure, Drug discovery, Bristol Myers Squibb, National Cancer Institute, Doctor of Philosophy, University, Organization, Medicine, Patient, George Washington University, Cancer, CD40, Pharmaceutical industry

Both Dr. Siegall and Dr. Sasser are highly successful executives and scientific pioneers who bring valuable industry experience to Shattuck.

Key Points: 
  • Both Dr. Siegall and Dr. Sasser are highly successful executives and scientific pioneers who bring valuable industry experience to Shattuck.
  • “It is a pleasure to welcome Clay and Kate, esteemed industry leaders, to our Board of Directors,” said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck.
  • Following the next clinical updates expected mid-year, we anticipate continued expansion of and future pivotal studies for SL-172154 in multiple indications.
  • Dr. Sasser holds a Ph.D. in Integrated Biomedical Sciences from the Ohio State University as well as a B.S.

Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
목요일, 2월 29, 2024
Research, Autoimmune disease, Anemia, Investment, Lung cancer, Patient, Mirvetuximab soravtansine, PLD, Cancer cell, AZA, Azacitidine, Neoplasm, Clinical trial, TP53, Fusion, Autoimmunity, G&A, Cancer research, NSCLC, AML, ASH, Inflammation, Conference, Safety, Collaboration, Pharmacokinetics, Insurance, Messenger, Research and development, Society, Event, Administration, Citigroup, Publication, Cancer, Pharmaceutical industry

Initial combination data from the Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in PROC expected mid-year 2024.

Key Points: 
  • Initial combination data from the Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in PROC expected mid-year 2024.
  • Shattuck Closes Financing: On December 21, 2023, Shattuck announced a $50 million public offering of common stock and concurrent private placement of pre-funded warrants.
  • Research and Development (R&D) Expenses: R&D expenses for the quarter ended December 31, 2023, were $15.2 million, as compared to $21.9 million for the quarter ended December 31, 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the quarter ended December 31, 2023 were $4.4 million, as compared to $4.8 million for the quarter ended December 31, 2022.

Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference

Retrieved on: 
수요일, 2월 28, 2024
SAN, Cancer, Therapy, Autoimmune disease, Conference, Kite Pharma, News

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in a panel discussion at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 6:10 a.m. PT/9:10 a.m.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in a panel discussion at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 6:10 a.m. PT/9:10 a.m.
  • ET.
  • Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section.
  • Following a live webcast, a replay will be available on the Company's website for approximately 30 days.

Shattuck Labs Announces Participation in Upcoming March Conferences

Retrieved on: 
월요일, 2월 26, 2024
Autoimmune disease, Webcast, Patient, Cancer

AUSTIN, TX and DURHAM, NC, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in multiple investor conferences in March 2024.

Key Points: 
  • AUSTIN, TX and DURHAM, NC, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in multiple investor conferences in March 2024.
  • Format: Fireside chat with covering analyst Yigal Nochomovitz, Ph.D.
    Presenters: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer and Andrew Neill, M.B.A., Shattuck’s Chief Financial Officer
    A live webcast of the presentations will be available on the Investors section of the Company’s website.
  • A replay of the webcast will be archived for up to 30 days following the presentation date.

Gracell Biotechnologies Acquisition Completed

Retrieved on: 
목요일, 2월 22, 2024
Acquisition, SAN, Cancer, ADS, AstraZeneca, Time in New York, Cayman Islands, Plan, Autoimmune disease, Agreement, Milestone, Bank, Form 6-K, Form, CICA, American depositary receipt, Companies Act, Security (finance), CVR, Sub

The acquisition was structured as a merger of Merger Sub with and into the Company with the Company surviving the merger as a wholly owned subsidiary of Parent (the “Merger”).

Key Points: 
  • The acquisition was structured as a merger of Merger Sub with and into the Company with the Company surviving the merger as a wholly owned subsidiary of Parent (the “Merger”).
  • As a result of the Merger, the Company ceased to be a publicly traded company and became a wholly owned subsidiary of Parent.
  • Such letters of transmittal must be completed before such holders can receive the applicable merger consideration.
  • Certificated ADS holders should wait to receive the letters of transmittal before surrendering their ADSs.

Immix Biopharma 12 Month Review Progress Update

Retrieved on: 
수요일, 2월 21, 2024
Boston University, Research, Autoimmune disease, Toxicity, Doctor of Philosophy, Boston Medical Center, PMID, Health, Multiple myeloma, Patient, Poster, Blood, Investigational New Drug, Presentation, Bank, Johnson & Johnson, GMP, BCMA, Amyloidosis, BioMarin Pharmaceutical, Autoimmunity, MBBS, Pfizer, ASH, European, IMS, Conference, ODD, Haematologica, IND, Public, Gene, MD, FDA, Food, U.S. FDA, Cell, ALA, Letter, Society, Publication, BMC, Pharmaceutical industry

LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder letter.

Key Points: 
  • LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder letter.
  • “The past 12 months have seen landmark achievements for Immix Biopharma, cementing our position as a leading cell therapy company in autoimmune disease.
  • NXC-201 is the first and only ‘Single-Day CRS‘ CAR-T, a critical advancement for autoimmune diseases like AL Amyloidosis,” said Ilya Rachman, MD PhD CEO Immix Biopharma.
  • As we reflect on the last 12 months of progress, we wish to connect with you offering an update on Immix Biopharma.

PolTREG appoints Dan Shelly as Chief Business Development Officer

Retrieved on: 
수요일, 2월 21, 2024
PATH, ALS, Autoimmune disease, PTG, Doctor of Philosophy, Prescient Therapeutics, University, MBA, Warsaw Stock Exchange, COVID-19, Therapy, CGMP, Patient, Multiple sclerosis, Biology, Research, Cancer, Pharmaceutical industry

“I am elated we were able to attract Dan to help us deliver the promise of Treg cell therapies for a wide range of autoimmune diseases.

Key Points: 
  • “I am elated we were able to attract Dan to help us deliver the promise of Treg cell therapies for a wide range of autoimmune diseases.
  • Dr Shelly is an astute veteran of the life science industry, with a deep understanding of biology and the Treg cell therapies that PolTREG is developing.
  • He was Director of Global Business Development and Strategic Partnerships for the global non-profit PATH, where he was the Co-Lead for the COVID-19 task force.
  • So far, PolTREG has successfully treated 27 patients with PTG-007 commercially under a hospital exemption program in Poland.